Palbociclib 125 mg

Available Products on This Website

Brand-specific packaging, dosage form, regulatory authorization and local product information should always be confirmed from the actual manufacturer documentation and applicable regulatory authority.

Incepta Pharmaceuticals Ltd. About the Manufacturer

Brand Name: Palbocent
Active Ingredient: Palbociclib
Strength: 125 mg
Manufacturer: Incepta Pharmaceuticals Ltd.

Product-specific details should be confirmed from official manufacturer documentation and packaging.

Incepta Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer in Bangladesh, established in 1999. The company develops and manufactures a wide range of pharmaceutical products for the domestic and international markets. 

Address: Incepta Pharmaceuticals Ltd., 40 Shahid Tajuddin Ahmed Sarani, Tejgaon I/A, Dhaka-1208, Bangladesh

Incepta Pharmaceuticals Ltd. Verification Process

Scan the QR code printed on the product box. The QR code will take you to the official Incepta product verification page, where you can complete the verification process.

The QR code will direct you to the Incepta Pharmaceuticals Ltd. e-verification page, where you can complete the product verification process.

After completing the verification, check the result carefully to confirm whether the product is genuine.

If the verification indicates that the product is fake or unauthorized, do not use it. Report the suspected counterfeit product and take appropriate legal action against the supplier through the Directorate Incepta of Drug Administration (DGDA), World.

Always purchase medicines from licensed pharmacies or authorized suppliers and verify the product before use.

Everest Pharmaceuticals Ltd. About the Manufacturer

Brand Name: Palboxen
Active Ingredient: Palbociclib
Strength: 125 mg
Manufacturer: Everest Pharmaceuticals Ltd.

Product-specific packaging and official prescribing information should be confirmed directly from the manufacturer and applicable regulatory documentation.

Head Office: Everest Pharmaceuticals Ltd. is located at Rahman’s Regnum Centre (10th & 11th floor), 191/1 Tejgaon Commercial Area, Dhaka-1208, Bangladesh.

Manufacturing Plant: Everest Pharmaceuticals Limited B-33, 45 & 46, BSCIC, Kanchpur, Narayanganj–1430, Bangladesh

Everest Pharmaceuticals Ltd. Product Verification Process

To verify the authenticity of an Everest Pharmaceuticals product, follow the verification process below:

Scan the QR Code: Scan the QR code printed on the product box.

The QR code will direct you to the official product verification page.

The QR code will direct you to the Everest Pharmaceuticals Ltd. E-Verification page, where you can complete the product verification process.

Open the Box: After accessing the verification page, open the product box and locate the verification code printed on the bottle.

Submit the Verification Code: Enter the verification code from the bottle on the verification page and submit it to check the product’s authenticity.

Verification Success: If the verification is successful, the product is confirmed as legitimate.

Verification Error: If the system displays a verification error, the product may be counterfeit or unauthorized. Do not use the product until its authenticity has been confirmed through an appropriate official channel.

Counterfeit Products: If a product is confirmed to be fake, do not use or distribute it. Report the suspected counterfeit product and supplier to the appropriate regulatory authorities, such as the Directorate General of Drug Administration (DGDA) in the world, and take appropriate legal action against the supplier through the relevant authorities.

Important: Always purchase medicines from licensed pharmacies or authorized suppliers and verify suspicious products before use.

What is Palbociclib?

Palbociclib is a prescription anticancer medicine belonging to a group of medicines called cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors.

It is used in specific treatment settings for certain types of hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer.

Palbociclib is generally used together with appropriate endocrine therapy, depending on the patient’s clinical condition, treatment history, menopausal status and applicable prescribing information.

Which Disease Is Palbociclib Used For?

Palbociclib is primarily used in approved treatment settings for:

• HR-positive breast cancer
• HER2-negative breast cancer
• Advanced breast cancer
• Metastatic breast cancer

It is not suitable for every type of breast cancer. Treatment selection depends on factors such as tumor biology, hormone receptor status, HER2 status, previous treatment and the patient’s overall medical condition.

How Does Palbociclib Work?

Palbociclib works by inhibiting CDK4 and CDK6, proteins involved in controlling the cell cycle.

Cancer cells must pass through different stages to grow and divide. CDK4 and CDK6 play an important role in progression through the G1 phase of the cell cycle.

By blocking these proteins, palbociclib can slow cell-cycle progression in susceptible cancer cells and reduce cancer-cell proliferation.

Palbociclib is therefore considered a targeted anticancer therapy.

Uses and Benefits

When used in an appropriate approved treatment setting, palbociclib may help:

• Slow the growth of susceptible cancer cells
• Delay disease progression
• Support endocrine therapy
• Provide a targeted treatment approach for appropriate HR-positive, HER2-negative breast cancer

However, treatment outcomes vary between patients. No website can predict how an individual patient will respond.

Active Ingredient and Strength

Active Ingredient

Palbociclib

Strength

125 mg

The 125 mg strength describes the amount of palbociclib contained in the relevant dosage unit.

A 125 mg strength does not mean that every patient should always receive that dose throughout treatment. Doctors may interrupt treatment or reduce the dose when clinically necessary.

Dosage and How to Take Palbociclib

Palbociclib must be taken exactly as prescribed by an oncology specialist.

The appropriate dose depends on:

• The approved treatment indication
• Other medicines being used
• Treatment tolerance
• Blood-test results
• Side effects
• Previous treatment history
• Applicable prescribing information

Patients should not independently increase, decrease or stop their dose.

When and How Often Is It Taken?

Palbociclib treatment follows a specific schedule determined by the applicable prescribing information and the treating oncology team.

A commonly used palbociclib treatment schedule involves treatment cycles with periods of medicine administration and planned breaks. However, the exact schedule should always follow the prescription and product information applicable to the individual patient.

Take the medicine according to the instructions provided by your doctor or pharmacist.

Should Palbociclib Be Taken Before or After Food?

Administration instructions can depend on the specific product formulation and applicable prescribing information.

Patients should follow the instructions supplied with their specific Palbocent or Palboxen product and the advice of their oncology team.

Do not change the way the medicine is taken without professional guidance.

Important Precautions and Warnings

Palbociclib requires regular medical supervision.

Important precautions include monitoring for:

• Low white blood cell counts
• Neutropenia
• Infection
• Anemia
• Low platelet counts
• Liver-related concerns where clinically relevant
• Serious lung symptoms

One of the most important risks is neutropenia, which is a reduction in neutrophils, a type of white blood cell important for fighting infection.

Regular blood tests may therefore be required.

Common Side Effects

Possible side effects can include:

• Low white blood cell counts
• Neutropenia
• Leukopenia
• Fatigue
• Hair thinning or hair loss
• Nausea
• Diarrhea
• Decreased appetite
• Stomatitis or mouth sores
• Anemia
• Thrombocytopenia
• Increased susceptibility to infection

The severity of side effects varies between patients.

Serious Side Effects

Serious reactions may include:

Severe Neutropenia

A significant reduction in neutrophils may increase the risk of infection.

Serious Infection

Patients should promptly report symptoms such as fever or other signs of infection.

Interstitial Lung Disease or Pneumonitis

New or worsening respiratory symptoms should receive prompt medical assessment.

Significant Blood-Cell Abnormalities

Palbociclib may affect:

• White blood cells
• Red blood cells
• Platelets

The treating healthcare team may interrupt or modify treatment if clinically significant abnormalities occur.

Who Should Avoid Taking Palbociclib?

Palbociclib may not be appropriate for every patient.

Patients should discuss treatment suitability with their oncology team, particularly if they have:

• A history of significant treatment intolerance
• Serious or uncontrolled infection
• Significant blood-count abnormalities
• Serious lung problems
• Pregnancy
• Plans for pregnancy
• Other important medical conditions

The final decision should be made by an appropriately qualified healthcare professional.

Drug Interactions

Palbociclib can interact with other medicines.

Important interactions may involve medicines that affect CYP3A-related metabolic pathways.

Some medicines can:

• Increase palbociclib exposure
• Decrease palbociclib exposure
• Increase the risk of adverse effects

Patients should inform their healthcare team about all:

• Prescription medicines
• Over-the-counter medicines
• Herbal products
• Vitamins
• Supplements

Food Interactions

Certain food products, including grapefruit and grapefruit-containing products, may be relevant to palbociclib treatment depending on the applicable product information.

Patients should discuss dietary restrictions and possible food interactions with their healthcare professional.

Pregnancy and Breastfeeding

Palbociclib may cause harm to a developing fetus.

Patients should discuss:

• Pregnancy status
• Pregnancy plans
• Appropriate contraception
• Potential fetal risks
• Breastfeeding

with their treating healthcare professional before and during treatment.

Available Strengths and Forms

This website specifically focuses on Palbociclib 125 mg products.

The availability of other strengths and dosage forms may vary according to:

• Manufacturer
• Country
• Regulatory approval
• Product availability

Patients should confirm the exact product and strength prescribed by their doctor.

Storage Instructions

Storage requirements should always be taken from the specific manufacturer’s packaging and official product information.

Patients should generally:

• Keep the medicine in its original packaging
• Protect it as instructed on the package
• Keep it away from children
• Do not use expired medicine
• Do not use damaged or suspicious packaging

The exact storage temperature and conditions should be verified from the Palbocent or Palboxen package leaflet.

Important Information Patients Should Know

Before starting Palbociclib 125 mg, patients should understand that:

1. Palbociclib is a prescription anticancer medicine.
2. It is not suitable for every type of breast cancer.
3. Treatment requires oncology supervision.
4. Regular blood tests may be necessary.
5. The dose may need adjustment because of side effects or blood-test results.
6. Patients should report fever and possible infection symptoms promptly.
7. Drug interactions can be clinically important.
8. Pregnancy precautions are important.
9. Patients should not change or stop treatment without medical advice.
10. The exact brand, manufacturer, batch number, and expiry date should be verified before use.

Medical Disclaimer

The information on Palbociclib125mg.com should be provided for general educational purposes only. It should not replace consultation with an oncologist, pharmacist or other qualified healthcare professional.

Palbociclib treatment is individualized, and the correct medicine, dose, treatment schedule and combination therapy must be determined by the treating oncology team.